|
Session 88
Poster Abstracts
Antiretroviral Therapy: Adherence, Health Care Costs and Access
Wednesday, 1:30 - 3:30 pm
Poster Hall |
531
 |
Proactive Telephone Support from a Central Site to Improve ART Adherence: A Multi-site, Randomized Controlled Trial ACTG 731, an Adherence Substudy of ACTG 384
Nancy Reynolds*1, M Testa2, M Su3, M Chesney4, J Neidig1, I Frank5, S Smith6, J Ickovics7, G Robbins8, and the ACTG 731 and ACTG 384 Teams
1Ohio State Univ, Columbus, US; 2Harvard Sch of Publ Hlth, Boston, MA, US; 3Phase V Tech, Boston, MA, US; 4Natl Ctr for Complementary and Alternative Med, NIH, DHHS, Bethesda, MA, US; 5Univ of Pennsylvania, Philadelphia, US; 6Agency for Hlthcare Res and Quality, Rockville, MD, US; 7Yale Univ, Hartford, CT, US; and 8Massachusetts Gen Hosp, Boston, US |
532
|
Initial Adherence and Other Psycho-social Factors among Predictors of Clinical Progression in HIV-infected Patients Initiating a PI-containing Regimen
V Villes1, V Le Moing2, C Lewden3, M Dupon4, D Peyramond5, P Morlat4, J M Ragnaud4, C Leport6, Bruno Spire*1, M Carierri1, and APROCO/COPILOTE (ANRS CO8) Study Group
1INSERM U379, Marseille, France; 2Montpellier Univ Hosp, France; 3Bordeaux Univ Hosp, INSERM U593, France; 4Bordeaux Univ Hosp, France; 5Lyon Univ Hosp, France; and 6Hosp Bichat, Paris, France |
533
|
Boosted PI Are more Forgiving of Suboptimal Adherence than Non-boosted PI or NNRTI
Robert Gross*1, B Yip2, E Wood2, D Bangsberg3, A Justice4,5, J Montaner2, and R Hogg2
1Univ of Pennsylvania, Philadelphia, US; 2Univ of British Columbia, Vancouver, Canada; 3Univ of California, San Francisco, US; 4Yale Univ, New Haven, CT, US; and 5VAMC, West Haven, CT, US |
534
|
The Acceptability of a Directly Administered ART (DAART) Model among Patients in Public HIV Clinics in Los Angeles County, California
W Garland1, A Wohl1, R Valencia1, M Witt2, K Squires3, A Kovacs3, R Larsen3, M Anthony4, S Hader4, and Paul J. Weidle*4
1Los Angeles County Dept of Hlth Svcs, CA, US; 2Harbor-Univ of California Med Ctr, Torrance, US; 3Univ of Southern California Med Ctr, Los Angeles, US; and 4CDC, Atlanta, GA, US |
| 535 |
Factors Associated with Plasma Viral Load Suppression among Injection Drug Users Attending Directly Observed Therapy Programs in Vancouver
Mark Tyndall*, E Wood, M McNally, R Zhang, C Lai, T Kerr, and J Montaner
BC Ctr for Excellence in HIV/AIDS, Vancouver, Canada |
| 536 |
Excellent Adherence Shifts Medical Costs from Inpatient Care to Prescription ART Costs
Edward Gardner*1,2, M Maravi1, W Burman1,2, C Rietmeijer1,2, and A Davidson1,2
1Denver Publ Hlth, CO, US and 2Univ of Colorado Hlth Sci Ctr, Denver, US |
| 537 |
Contemporary Costs of HIV Health Care in the HAART Era
Kelly Gebo*1, J Fleishman2, R Conviser3, J Hellinger4, F Hellinger2, P Keiser5, P Gaist6, R Moore1, and for the HIV Res Network
1Johns Hopkins Univ, Baltimore, MD, US; 2Agency for Hlthcare Res and Quality, Rockville, MD, US; 3Hlth Resources and Svcs Admin, HIV/AIDS Bureau, Rockville, MD, US; 4Community Med Alliance, Boston, MA, US; 5Parkland Hlth and Hosp Systems, Dallas, TX, US; and 6NIAID, NIH, DHHS, Bethesda, MD, US |
| 538 |
Optimizing Access to AIDS Drug Assistance Programs: First-come First-served vs CD4-based Enrollment
Benjamin P Linas*1, H Zheng1, E Losina1,2, A Rockwell3, R Walensky1, K Cranston3, and K Freedberg1,2
1Massachusetts Gen Hosp, Boston, US; 2Boston Univ Sch of Publ Hlth, MA, US; and 3Massachusetts Dept of Publ Hlth, Boston, US |
|
